Are you in compliance?

Don't miss out! Sign up today for our weekly newsletters and stay abreast of important GRC-related information and news.


Status message

Start your free, no obligation 5-day trial to continue exploring with full access.

Bribery Probe Ends with Charges Against Former GSK China Top Executive

Roberta Holland | May 21, 2014

China has wrapped up a 10-month bribery investigation into pharmaceutical giant GlaxoSmithKline's operations there, resulting in bribery charges against the former head of GSK China, according to Chinese law enforcement and published reports.

Mark Reilly, a British national who served as managing director of GSK China, is accused of ordering subordinates to commit bribery in order to boost drug sales for the U.K.-based company, according to the official Chinese news service Xinhua. Xinhua reported that law enforcement officials had finished a 10-month bribery investigation involving GSK, and found that Reilly allegedly pressed his sales teams to bribe hospitals, doctors, and other health-care institutions, resulting in billions of yuan in increased revenue.


Read this single article for $49, or click the subscribe button below to review subscription options.

Enjoy unlimited access to thousands of articles, browse five years of digital magazines, qualify for reduced admission to events, and more.